1	The effects of inhaled corticosteroids on healthy airways
2	¹ Emanuele Marchi, PhD*, ¹ Timothy S.C. Hinks, FRCP, PhD*, ² Matthew Richardson, PhD,
3	² Latifa Khalfaoui [§] , PhD, ² Fiona A. Symon PhD, ³ Poojitha Rajasekar, BSc, ³ Rachel Clifford,
4	PhD, ² Beverley Hargadon RGN, ⁴ Cary D. Austin MD, PhD, ⁵ Julia L. MacIsaac, PhD, ⁵ Michael
5	S. Kobor, PhD, ² Salman Siddiqui [§] , FRCP, ⁴ Jordan S. Mar, PhD, ⁴ Joseph R. Arron MD, PhD,
6	⁴ David Choy BSc, ² Peter Bradding FRCP, DM.
7	¹ NIHR Oxford Respiratory BRC and Respiratory Medicine Unit, Experimental Medicine,
8	Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, UK.
9	² Department of Respiratory Sciences, University of Leicester, Leicester Respiratory NIHR
10	BRC, Glenfield Hospital, Leicester, UK.
11	³ Centre for Respiratory Research, Translational Medical Sciences, School of Medicine;
12	Nottingham NIHR Biomedical Research Centre; and Biodiscovery Institute, University Park,
13	University of Nottingham, Nottingham, UK.
14	⁴ Genentech, Inc. South San Francisco, CA, USA.
15	⁵ Edwin S.H. Leong Centre for Healthy Aging, Department of Medical Genetics, University
16	of British Columbia, Vancouver, Canada.
17	*These authors contributed equally to this manuscript.
18	
19	Corresponding author
20	Professor Peter Bradding, Department of Respiratory Sciences, University of Leicester,

- Glenfield Hospital, Leicester, LE3 9QP, UK. Tel: +44 116 258 3998 21
- 22 E-mail: pb46@le.ac.uk NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

2

Running title: The effects of ICS on healthy airways

24	Funding sources: This work was supported by an investigator-led grant from Genentech to
25	the University Hospitals of Leicester NHS Trust, and supported in part by the National Institute
26	for Health Research (NIHR) Leicester Biomedical Research Centre (Respiratory). EM is
27	supported by Asthma+Lung UK (WADR22\100015). TSCH is supported by a Wellcome Trust
28	Fellowship (211050/Z/18/z). RLC is supported by a University of Nottingham Anne McLaren
29	Fellowship. All authors had full access to the data in the study and accept responsibility to
30	submit for publication. The views expressed are those of the authors and not necessarily those
31	of the NHS, the NIHR or the Department of Health.
32	
33	Author contributions
34	All authors reviewed the data and contributed to its interpretation, edited the manuscript, and
35	approved the final submitted version.
36	Specific contributions:
37	EM: Analysed the RNA seq data and drafted the manuscript
38	TSCH: Contributed to data analysis and interpretation, and drafting of the manuscript.
39	MR: Analysed the RNA seq data.
40	LC and FAS: Performed immunohistochemistry, and quantified and collated the data.
41	PR: performed and analysed DNA methylation studies
42	RLC: Designed, supervised and analysed DNA methylation studies.
43	BH: Managed the study, contributed to patient recruitment, collated the demographic data.
44	CDA: Contributed to bronchoscopy protocol design.

	-	
1	-	
	-	
٠	_	
	_	

- 45 JLM and MSK performed DNA methylation studies.
- 46 **SS**: Analysed the RNA seq data.
- 47 **JRA:** Conceived and designed the study.
- 48 **DC:** Conceived and designed the study, analysed RNA seq data, drafted the manuscript.
- 49 **PB**: Conceived and designed the study, wrote the study protocol and ethical application,
- 50 analysed the data, drafted the manuscript, performed all bronchoscopies. Chief investigator.

51

```
52 <sup>§</sup> Current addresses:
```

- 53 Latifa Khalfaoui Mayo Clinic, Rochester, Minnesota, USA
- 54 Salman Siddiqui National Heart and Lung Institute, Imperial College, London, UK

55

56 **DESCRIPTOR**: 3.32 Airway gene expression

57

58 This article has an online supplement

59

60 Word Count: 3493

4

62 ABSTRACT

Rationale: The effects of inhaled corticosteroids (ICS) on healthy airways are poorly defined. **Objectives:** To delineate the effects of ICS on gene expression in healthy airways, without
confounding caused by changes in disease-related genes and disease-related alterations in ICSresponsiveness.

Methods: Randomised open-label bronchoscopy study of high dose ICS therapy in 30 healthy
adult volunteers randomised 2:1 to i) fluticasone propionate 500 mcg bd or ii) no treatment, for
4 weeks. Laboratory staff were blinded to allocation. Biopsies and brushings were analysed by
immunohistochemistry, bulk RNA sequencing, DNA methylation array and metagenomics.

Measurements and main results: ICS induced small between-group differences in blood and 71 lamina propria eosinophil numbers, but not in other immunopathological features, blood 72 73 neutrophils, FeNO, FEV₁, microbiome or DNA methylation. ICS treatment upregulated 72 genes in brushings and 53 genes in biopsies, and downregulated 82 genes in brushings and 416 74 75 genes in biopsies. The most downregulated genes in both tissues were canonical markers of 76 type-2 inflammation (FCER1A, CPA3, IL33, CLEC10A, SERPINB10 and CCR5), T cell-77 mediated adaptive immunity (TARP, TRBC1, TRBC2, PTPN22, TRAC, CD2, CD8A, HLA-DQB2, CD96, PTPN7), B cell immunity (CD20, immunoglobulin heavy and light chains), and 78 79 innate immunity, including CD48, Hobit, RANTES, Langerin and GFI1. An IL-17-dependent gene signature was not upregulated by ICS. 80

81 Conclusions: In healthy airways, 4-week ICS exposure reduces gene expression related to both 82 innate and adaptive immunity, and reduces markers of type-2 inflammation. This implies that 83 homeostasis in health involves tonic type-2 signalling in the airway mucosa, which is 84 exquisitely sensitive to ICS.

85 Abstract word count: 249

5

86

87 Key Words asthma, health, bronchial biopsy, transcriptome, epigenetics

6

89 Abbreviations

- 90 ASM airway smooth muscle
- 91 FeNO fraction of exhaled nitric oxide
- 92 FEV_1 forced expiratory volume
- 93 ICS inhaled corticosteroid
- 94 IQR -interquartile range
- 95 MBP major basic protein
- 96 MC_T tryptase only mast cell
- 97 MC_{TC} tryptase and chymase mast cell
- 98 PG prostaglandin
- 99 RBM reticular basement membrane
- $100 \quad RTU ready-to-use$
- 101 SD standard deviation
- 102 T2 Type-2 cytokines (IL-4, IL-5, IL-13)

7

103 INTRODUCTION

104 Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment. They attenuate eosinophilic airway inflammation(1,2), improve lung function, and reduce asthma symptoms, 105 106 exacerbations, and mortality(3). However, their use is also associated with an increased risk of 107 pneumonia(4). Corticosteroids modulate the expression of many molecular pathways at the level of gene transcription, through direct upregulation of anti-inflammatory molecules and β-108 adrenoceptors (transactivation), and suppression of pro-inflammatory genes, either through 109 direct DNA-binding or via inhibition of pro-inflammatory transcription factor binding 110 (transrepression)(5). In people with severe asthma, ICS are relatively ineffective even at high 111 doses, but the mechanisms behind this corticosteroid insensitivity are poorly understood and 112 likely multi-factorial(6,7). 113

114 When considering the underlying molecular pathways driving both severe asthma and relative 115 corticosteroid insensitivity, it is unclear to what extent this is driven by pathways that are not responsive to corticosteroids, as opposed to inhibition of corticosteroid signalling. Gene 116 expression profiling in asthmatic epithelial bronchial brushings and bronchial biopsies has 117 identified several molecular pathways present in subgroups of patients with mild, moderate and 118 severe asthma(8,9). Approximately 80% of people with steroid-naïve "mild" asthma 119 demonstrate evidence of blood or airway eosinophilia, with a concomitant increase in the 120 fraction of exhaled nitric oxide (FeNO)(10,11). This phenotype is characterised by increased 121 expression of an airway gene expression signature driven by IL-4 and IL-13(8,9,12,13); tissue 122 123 eosinophilia is also dependent on IL-5(14). Together these cytokines are described as Th2 or type-2 cytokines (T2). T2 expression and the accompanying eosinophilia are suppressed by 124 ICS in mild asthma(15). In severe asthma, a persistent T2 gene signature is evident in about 125 126 25% of patients, suggesting corticosteroid insensitivity(8,9). In addition, in severe asthma,

8

about 25% of patients have evidence of an IL-17-dependent gene signature, which is seen only 127 in people on ICS(8,9), and mutually exclusive with the T2 signature. It is therefore not clear 128 129 whether this IL-17 activity represents an independent corticosteroid-insensitive pathway driving severe asthma or a consequence of ICS therapy. Approximately 50% of people with 130 severe asthma have neither a T2- or IL-17-dependent airway gene signature, and the 131 mechanisms driving their persistent disordered airway physiology remains unknown. So, while 132 gene expression profiling provides insight into the abnormalities present in severe asthmatic 133 134 airways, the multiple effects of ICS on airway gene expression make it difficult to disentangle the changes due to the disease as opposed to the treatment, and whether corticosteroid activity 135 is inhibited or not. 136

The effects of ICS on healthy airways are poorly defined. We hypothesise that gene expression data in severe asthma will be more interpretable if we can delineate and thus allow for the effects of high dose ICS therapy. We have therefore performed a randomised open label bronchoscopy study of high dose ICS therapy in healthy adult volunteers, with the aim of understanding transcriptional consequences of ICS therapy without the confounding effects due to disease-related processes.

9

144 METHODS

- 145 Detailed methods are provided in the online data supplement.
- 146 This prospective study was approved by the East Midlands-Leicester Central Research Ethics
- 147 Committee (reference:15/EM/0313) and registered at clinicaltrials.gov (NCT02476825).
- 148 Participants gave written informed consent.

149 **Participant population**

Healthy volunteers aged 18-65 were eligible, were current non-smokers with <10 pack year smoking history, and had no prior history or clinical evidence of lower respiratory disease with normal spirometry. Participants with a history of rhinitis were required to have a PC_{20} methacholine >16 mg/ml.

154 Study design

This was a randomised, open-labelled, bronchoscopy study designed to assess the effects of 4 weeks treatment with fluticasone propionate on airway gene expression and cellularity in healthy adult volunteers. The primary endpoint was the corticosteroid-inducible gene expression pattern in healthy airways. Secondary endpoints included the relative change from baseline in airway cellularity.

30 participants were randomised by a blinded investigator (MR) in a 2:1 ratio to one of two study groups: i) fluticasone propionate 500 mcg b.i.d. via Accuhaler (Diskus) for 4 weeks (n=20), or ii) no treatment (observation) for 4 weeks (n=10). Bronchoscopy was performed at baseline prior to the start of treatment/observation, and at the end of week 4. Genentech and Leicester laboratory support staff were blinded to treatment allocation.

10

165	To ensure there	were sufficien	t data for	[.] analysis,	if a subject	withdrew	before	completion of	of

- the study, a further subject(s) was randomised after the first 30 randomisations until a total of 166
- 30 subjects had completed the study. 167

Bronchoscopy 168

- 169 Subjects underwent bronchoscopy conducted according to British Thoracic Society guidelines(16). Mucosal biopsies and brushes were collected from 2nd-5th generation bronchi 170
- under direct vision as per study procedure manual. 171

.....

Tissue processing, immunohistochemistry and assessment of immunopathology 172

- Please see the online supplement. 173
- All pathological data were assessed by an observer blinded to the identity and treatment 174
- allocations of the participants. 175

176 **RNA** sequencing

- Please see the online supplement. 177
- Bisulphite conversion and DNA methylation arrays. DNA methylation data quality 178
- control and normalization, Differential DNA methylation analysis, Expression 179
- quantitative trait methylation (eQTM) analysis 180
- Please see the online supplement. 181
- Microbiota Sequence Data Generation, Processing, and Analysis 182
- Please see the online supplement. 183

11

184 **Transcriptomic analysis**

- 185 Sequences in fastq files (in single and pair ends) were aligned using STAR aligner (version
- 186 2.7.1a) to the human reference genome GRCh38; R package (17)Rsubread was employed for
- 187 quantification of reads assigned to genes.
- 188 Raw count pre-processing, normalisation and differential gene expression analysis was
- 189 performed using R packaged DESeq2, edgeR, and limma. Gene pathways enrichment analysis
- 190 was executed using R packages fgsea, clusterProfile, and ReactomePA. Heatmaps, volcano and
- 191 MA plots were generated using in-home R code, ggplot2 and plotly packages(17,18).

192 Statistical analysis

Basic summary statistical analysis was performed using GraphPad Prism version 7.03
(GraphPad Software, San Diego). Parametric and non-parametric data are presented as mean
(standard deviation [SD]) and median (interquartile range [IQR]) respectively unless otherwise
stated.

197 RESULTS

Clinical characteristics 198

We recruited 44 healthy participants. 32 proceeded to bronchoscopy but one patient withdrew 199 from the study after the first bronchoscopy. 31 completed 2 bronchoscopies, but one was 200 201 subsequently withdrawn due to both <80% medication adherence and an intercurrent asymptomatic bronchitis evident at the 2nd bronchoscopy (with bronchial wash samples 202 positive for a non-Covid coronavirus and Staphylococcus aureus). The clinical characteristics 203 of the 30 participants completing the study are shown in table 1. 204

Effects of ICS on biomarker and physiological measurements 205

There was a significant increase in blood eosinophil numbers after 4 weeks in the observation 206 group compared to people using ICS, but this was not related to atopic status (Supplementary 207 208 figure E1A). There were no significant between-group differences for changes in blood neutrophils, FeNO or FEV₁ (Supplementary figure E1B-D). 209

Effects of ICS on airway inflammatory and structural cells 210

211 Suitable paired samples for immunohistochemical analysis of the lamina propria were available from 17 participants receiving ICS and 8 undergoing observation (Figure 1 and 212 213 **Supplementary Figure E2**). Although there was no significant change in lamina propria eosinophil counts within either group from the 1st to 2nd bronchoscopy, there was a significant 214 between-group difference in the changes (p=0.01), due to a non-significant increase in the 215 216 observation group (Figure 1A). There was no correlation between the change in blood eosinophils versus tissue eosinophils in the observation group (r_s = -0.024, p=0.97). Comparing 217 the changes in measurements from the 1st to 2nd bronchoscopy for the ICS versus the 218 observation group, there were no significant differences between treatment groups for lamina 219 propria neutrophil, tryptase+ or chymase+ mast cell counts, airway smooth muscle (ASM) and 220

13

221 epithelial area expressed as a percentage of biopsy area, or reticular basement membrane depth
222 (Figure 1B-G)(Supplementary Figure E2).

223 Effects of ICS on airway gene expression

Suitable paired brush and biopsy samples were available for 15 and 20 participants respectively 224 225 receiving ICS. We observed significant differential expression of genes amongst participants 226 at week 4 compared with baseline in the ICS-treatment group, with upregulation of 72 genes in brushings and 53 genes in biopsies, and downregulation of 82 genes in brushings and 416 227 genes in biopsies (Figure 2, Supplementary Tables E1-E4, Supplementary Figures E3, E4). 228 Amongst participants in the observation-only group there were no significant changes in gene 229 230 expression observed between baseline and week 4 (Supplementary Figure E5). There was a close correlation between epithelial brush and bronchial biopsy gene expression, with 20 genes 231 common to the top 24 most significantly differentially upregulated genes in both airway 232 233 compartments (Table 2) and 20 genes common to the top 41 most significantly downregulated genes in both compartments (Table 3). 234

The most significantly upregulated genes were predominantly those involved in steroid 235 metabolism (HSD11B2, FKBP5, SULT2B1, SYT8, and SLCO1B3), cellular proliferation 236 237 (PSCA, TFCP2L1, IFITM10, ANPEP), cellular metabolism (GRAMD2A, PRODH, GNMT) and cytoskeletal changes (PHACTR3, FAM107A). By contrast genes which were most 238 239 significantly downregulated in both brushings and biopsies were key components of T2-driven inflammation (FCER1A, CPA3, IL33, CLEC10A, SERPINB10 and CCR5) and T cell-240 mediated adaptive immunity (TARP, TRBC1, TRBC2, PTPN22, TRAC, CD2, CD8A, HLA-241 DQB2, CD96, PTPN7) and (Table 3). All other top 20 common downregulated genes were 242 involved with innate or adaptive immunity, including the transcription factor Hobit (ZNF683) 243 which promotes lymphocyte tissue residency, the chemokine RANTES (CCL5), the antigen 244

14

presentation-associated molecule Langerin (CD207), and the growth factor GFI1 which is
involved in haematopoiesis, especially of neutrophils. In addition, there was downregulation
of genes associated with B cell function and immumunoglobulin production (CD20/79, most
heavy and variable light chains for IgA, IgG and IgM, JCHAIN), protective innate immunity
(e.g. CD48, CD163), mast cell proteases (TPSB1, TPSAB1, CPA3), the beta chain of the high
affinity IgE receptor (MS4A2), and prostaglandin D2 synthase (PTGDS1).

251 Consistent with these findings, pathway analysis of bronchial brushings with Reactome showed strong ICS-related downregulation of innate and adaptive pathways, 252 including 253 'Immunoregulatory interactions between a lymphoid and non-lymphoid cell', five pathways related to TCR signaling, the immunological synapse or co-stimulation, with weaker signals 254 for 'Generation of second messenger molecules', 'PD-1 signaling', and 'Chemokine receptors 255 256 *bind chemokines*', showing the potent ability of ICS to suppress local adaptive T cell immunity (Supplementary Figures E6, Supplementary Table E5). Parallel analysis of the bronchial 257 biopsies again showed effects on lymphoid – non-lymphoid interactions and TCR signaling, 258 but also strong suppression of 'Extracellular matrix organization', 'Cell surface interactions 259 at the vascular wall' and 'Integrin cell surface interactions', suggesting the potential for 260 261 suppression of inflammatory cell recruitment to the mucosa (Supplementary Figure E7, Supplementary Table E6). ICS did not upregulate the IL-17-dependent gene signature 262 263 identified previously in people with moderate-severe asthma (Supplementary Fig.E8)

Next we compared our set of differentially upregulated genes with a set of 26 genes previously reported as induced by 10 weeks of inhaled fluticasone in bronchial brushings from participants with mild asthma(19). Geneset enrichment analysis profiles showed very close agreement between genesets (**Supplementary Figure E9**), particularly for brushings, which were directly

15

- comparable between studies, showing very similar ICS-induced gene induction in health and
- 269 mild asthma.
- 270 Effects of ICS on the airway microbiome
- 271 Minimal effects of ICS treatment were observed on the airway microbiome (details in
- 272 Supplementary Results and **Supplementary Figure E10**).
- 273 Effects of ICS on airway DNA methylation
- 274 There were minimal effects of ICS treatment on DNA methylation (details in Supplementary
- 275 Results and **Supplementary Figure E11**).

16

277 **DISCUSSION**

In this open label, randomised study in healthy adult volunteers, we have defined genes that are altered directly by medium-term (4 weeks), twice daily high-dose ICS therapy independent of the confounding effect of asthma pathophysiology. Changes in airway cellularity were minimal between ICS treatment and no treatment, and there were no measurable biologically significant effects on the airway microbiome or DNA methylation.

By contrast, we observed widespread changes in gene expression following ICS use in 283 these healthy individuals, which predominantly comprised downregulated genes. A striking 284 finding was that the most significantly downregulated genes statistically were canonical 285 286 markers of T2-driven inflammation. Notably the most highly downregulated gene, in both airway brushes, which predominantly sample the airway epithelium, and mucosal biopsies, was 287 FCER1A which encodes the α chain of the high affinity IgE receptor, a key effector component 288 289 of mast cell activation by allergens and of T2 immunity, which is highly upregulated in asthma (20,21). In addition, there was downregulation of genes encoding mast cell tryptases (TPSB1, 290 TPSAB1) and carboxypeptidase A3 (CPA3), the beta chain of the high affinity IgE receptor 291 (MS4A2), and prostaglandin D2 synthase (PTGDS1). We did not see a reduction in mast cell 292 numbers in the airway mucosa of these healthy individuals, so the predominant effect of ICS 293 294 appears to be on gene transcription, rather than mast cell survival, but nevertheless suggests that ICS have a potentially important dampening effect on mast cell function. In biopsies, there 295 was also downregulation of the important mast cell chemoattractants CXCL10 and CXCL11 296 297 which promote mast cell migration to the ASM in mild steroid-naive asthma through the airway mast cell chemokine receptor CXCR3(22). In people with severe asthma using high dose ICS 298 +/- oral corticosteroids, mast cells are not increased within the ASM (23,24), suggesting 299 300 suppression of mast cell chemoattractants from ASM may remain corticosteroid-sensitive in

17

severe disease. This is in contrast to the release of mast cell-derived proteases and autacoids
which demonstrate ongoing release in severe disease(23,25).

Other highly downregulated T2-related genes included IL33, an airway epithelial cell 303 304 alarmin which acts to promote initiation of T2 responses(26), CLEC10A which is a marker for 305 alternatively activated macrophages(27), SERPINB10 which is highly upregulated on airway epithelium by IL-13 and inhibits Th2 cell apoptosis, and CCR5 whose ligands include CCL5 306 (RANTES), a chemoattractant for eosinophils and mast cells. Moreover PTGS1, which 307 encodes cyclooxygenase-1 was the 7th most downregulated gene in brushings. This enzyme 308 309 converts arachidonate to prostaglandins and its dysregulation or inhibition is implicated in salicylate-sensitive asthma and sino-nasal eosinophilic inflammation(28). Similarly in 310 biopsies, periostin (POSTN), an IL-13-induced epithelial gene associated with T2 high 311 312 asthma(29), was also downregulated.

313 Taken together, the ability of ICS to downregulate this extensive set of T2-related genes implies that homeostasis in health involves a low level of tonic T2 signalling in the airway 314 mucosa that is very sensitive to ICS. This would be consistent with the observation that IL-4-315 and IL-5-positive cells are present in healthy airways(30), as are mast cells and dendritic cells 316 expressing FccRIa(31). Constitutive T2 signalling is also evident in primary epithelial cell 317 318 cultures grown at air-liquid interface, where we previously observed that STAT6-dependent genes including POSTN, CLCA1 and SERPINB2 were repressed by NFkB-dependent 319 cytokine stimulation or dexamethasone(32). Thus differentiated bronchial epithelial cells have 320 a low level of tonic STAT6 dependent signalling in the absence of exogenous IL-4 or IL-13. 321 However, FeNO was not reduced by ICS in these healthy volunteers, and NOS2, which 322 regulates FeNO production, was not altered by ICS therapy, suggesting tonic T2 signalling is 323 below the threshold required for pathological FeNO generation. 324

18

325 The role of low-level, tonic, constitutive T2 signalling in the airways is uncertain but likely beneficial for tissue homeostasis. T2 immunity exhibits many host-protective functions, 326 327 including maintaining metabolic homeostasis, suppressing excessive T1 inflammation, 328 maintenance of barrier defence and regulation of tissue regeneration(33-36). For example, IL-33 is pleiotropic and can promote type 2 inflammation but in other contexts it can be 329 immunoregulatory(26), and preserves epithelial integrity during influenza infection in a mouse 330 model(37,38). Thus the effects of type 2 immunity may be context specific and affected by the 331 332 cellular source and concomitant inflammatory milieu, and at steady state may promote airway epithelial barrier function. Inhibition of homeostatic tonic T2 signalling might therefore have 333 deleterious effects which may have an impact clinically, and might explain an enhanced 334 335 propensity to proteobacterial colonisation or infection, as was observed in the MEX(39) and RASP-UK(40) studies amongst participants with very low T2 biomarkers. 336

In addition to the inhibition of T2-driven genes, there was marked suppression of molecules 337 involved in both protective innate immunity (e.g. CD48, CEACAM5) and adaptive immunity, 338 with suppression of genes related to dendritic cells (CD207), T cells (e.g. CD2/3/6/8/96, 339 TRBC1/2, TRAC), and B cell function (e,g, CD20/79, most heavy and variable light chains for 340 341 IgA, IgG and IgM, JCHAIN). This potential impairment of innate, cell-mediated and antibodydependent immunity likely explains the reproducible dose-dependent increased pneumonia risk 342 in people with asthma and COPD who are using ICS(4). A subgroup of people with asthma 343 344 also become colonised with certain fungi(41), and it is possible that this is also a consequence of the mucosal immunosuppression observed here. 345

An important aim of this study was to provide information on the activity of ICS in healthy 346 airways, to remove the confounding that might occur due to disease-related changes in gene 347 348 expression or inherent ICS responsiveness, which should facilitate analyses of gene expression

19

349 changes in asthma. Studies of severe asthma to-date (42) have attempted to account for the effects of ICS based on gene expression changes derived from in vitro cell cultures, from an 350 351 interventional study of gene expression changes in people administered ICS for chronic obstructive pulmonary disease, and from one previous intervention study which used 352 microarrays to assess acute airway transcriptional consequences 6 hours after a single inhaled 353 dose of budesonide (1600 µg) in 12 healthy, steroid-naïve men(43). Our findings are 354 complementary to the previous budesonide study in that some differentially regulated genes 355 356 are common to our two studies (including upregulation of FKBP5, ZBTB16, PHACTR3, TSC22D3 and downregulation of CD207, FCER1A, IL33), but there is a striking difference in 357 the overall consequences of a single dose versus 4 weeks twice daily ICS use. The predominant 358 359 effect of a single large acute dose of ICS was upregulation of genes (transactivation), with 68 genes upregulated and only 28 downregulated. Many of the upregulated genes were 360 proinflammatory including growth factors, chemokines, chemokine receptors, cytokines, 361 growth factors, and coagulation factors. By comparison in our chronic high dose exposure 362 study only 53 genes were upregulated in biopsies, whilst 416 genes were downregulated 363 364 (transrepression). This highlights the critical and often overlooked importance of the complex temporal dynamics of corticosteroid effects. Early during an acute infectious or traumatic 365 challenge a surge in endogenous corticosteroids will tend to enhance protective inflammatory 366 367 and procoagulant responses, but as time passes these responses will attenuate and slower but potent transrepressive effects will dominate to curtail uncontrolled inflammatory cell 368 recruitment and activation, to prevent bystander tissue damage, and to direct resolution of tissue 369 370 homeostasis. It is this latter situation which is of greatest clinical relevance to long term asthma management. Of note, comparing our data to the study by Woodruff(12), where people with 371 mild asthma received inhaled placebo or fluticasone propionate (500 µg) twice daily for 8 372

20

weeks, there was a strong correlation between the studies for ICS-inducible genes, suggestingthat in mild asthma at least, ICS-dependent transactivation is preserved.

When considering previous studies of gene expression in severe asthma, an IL-17-375 376 dependent gene signature is expressed in a subset of people, and mutually exclusive with a T2 gene signature (8.9). This IL-17-dependent signature was only seen in people using ICS, but it 377 has been unclear whether this is disease- or treatment-related, and whether it is harmful or 378 potentially protective. We did not see upregulation of this IL-17 signature after 4 weeks of ICS 379 treatment in this study, thus it seems most likely a feature of disease. Similarly, there is 380 381 upregulation of CEACAM family members in severe asthma, notably the IL-13-dependent gene CEACAM5(44,45), and CEACAM6 which was increased on both the epithelium and 382 neutrophils in bronchial biopsies(44). Here we found that CEACAM6 expression did not 383 384 change with ICS treatment, while CEACAM5 expression was reduced (tables E2, E4), in keeping with the inhibition of other T2-related genes. Therefore the upregulation of these 385 CEACAMs in severe asthma appears to be a feature of the disease rather than treatment. In the 386 recent U-BIOPRED bronchoscopy study(24), ICS-inducible genes such as FKBP5 were 387 upregulated in severe asthma, suggesting that their participants were adherent to treatment, and 388 389 importantly, that ICS transactivation appears to be preserved in severe asthma, but many pathological pathways that should be sensitive to transrepression by ICS such as T2 signalling 390 391 are not responsive in a subset of patients(8,9,23).

There are some limitations to our work. Firstly the effects of ICS in healthy airways at 4 weeks, while likely representative of the steady state in long term therapy, might not be fully representative of longer term therapy. However it is not reasonable to ask healthy volunteers to take ICS for a year, and adherence would likely wane. Secondly our analyses use bulk sequencing of airway brushes and biopsies, and ICS effects are likely to be highly cell-specific,

21

so future studies using spatial sequencing, from central and peripheral airways as well as nasal tissues and peripheral blood would be informative. For example, as we did not enumerate all of the cell types implicated in the transcriptomic analyses, we cannot conclude whether the changes in T- and B-lymphocyte related gene expression are due to transcriptional changes within lymphocytes, changes in the relative proportions of lymphocytes in the samples, or a combination of the two.

In summary, we defined genes altered directly by ICS therapy without confounding by disease. We provide evidence that IL-17-dependent signalling in asthma is disease-dependent rather than ICS-dependent, and demonstrate downregulation of canonical markers of T2 inflammation, implying that homeostasis in health involves tonic T2 signalling in the airway mucosa, which is exquisitely sensitive to ICS. There was also broad suppression of innate and adaptive immunity, in keeping with known immunosuppressive effects of corticosteroids.

22

410 Acknowledgements

411 The authors are grateful to all the participants who volunteered and to the clinical and research teams at all the participating centres. For the purpose of Open Access, the author has applied a 412 413 CC BY public copyright licence to any Author Accepted Manuscript version arising from this 414 submission. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The authors vouch for the integrity and 415 completeness of the data and the fidelity of the trial to the protocol. This study has been 416 conducted in accordance with the Declaration of Helsinki and any applicable regulatory 417 418 requirements.

419 Data sharing

The data analysed and presented in this study are available from the corresponding author on reasonable request, providing the request meets local ethical and research governance criteria after publication. Patient-level data will be anonymised. The RNA Sequencing data have been deposited in the Gene Expression Omnibus (GEO) under accession number GSE242048.

424

425

perpetuity. It is made available under a CC-BY 4.0 International license .

23

427 **REFERENCES**

- Laitinen LA, Laitinen A, Haahtela T. A comparative study of the effects of an inhaled corticosteroid,
 budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed
 asthma: a randomized, double-blind, parallel-group controlled trial. *J Allergy Clin Immunol*1992; 90: 32-42.
- 2. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls, AF, Roche WR, Howarth PH, Holgate ST.
 Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. *Am Rev Respir Dis* 1992; 145: 669-674.
- 435 3. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the
 436 prevention of death from asthma. *N Engl J Med* 2000; 343: 332-336.
- 437 4. McKeever T, Harrison TW, Hubbard R, Shaw D. Inhaled corticosteroids and the risk of pneumonia
 438 in people with asthma: a case-control study. *Chest* 2013; 144: 1788-1794.
- 439 5. Jaffuel D, Demoly P, Gougat C, Balaguer P, Mautino G, Godard P, Bousquet J, Mathieu M.
 440 Transcriptional potencies of inhaled glucocorticoids. *Am J Respir Crit Care Med* 2000; 162:
 441 57-63.
- 6. Chachi L, Shikotra A, Duffy SM, Tliba O, Brightling C, Bradding P, Amrani Y. Functional KCa3.1
 channels regulate steroid insensitivity in bronchial smooth muscle cells. *J Immunol* 2013;
 191: 2624-2636.
- 7. Alzahrani A, Hussain A, Alhadian F, Hakeem J, Douaoui S, Tliba O, Bradding P, Amrani Y. Potential
 Role of Mast Cells in Regulating Corticosteroid Insensitivity in Severe Asthma. *Adv Exp Med Biol* 2021; 1303: 1-12.
- 8. Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E,
 Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas
 AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P.
 TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. *Sci Transl Med*2015; 7: 301ra129.
- 9. Ostling J, van Geest M, Schofield JPR, Jevnikar Z, Wilson S, Ward J, Lutter R, Shaw DE, Bakke PS,
 Caruso M, Dahlen SE, Fowler SJ, Horvath I, Krug N, Montuschi P, Sanak M, Sandstrom T, Sun
 K, Pandis I, Auffray C, Sousa AR, Guo Y, Adcock IM, Howarth P, Chung KF, Bigler J, Sterk PJ,
 Skipp PJ, Djukanovic R, Vaarala O, Group UBS. IL-17-high asthma with features of a psoriasis
 immunophenotype. J Allergy Clin Immunol 2019; 144: 1198-1213.
- 458 10. Berry MA, Morgan A, Shaw DE, Parker D, Green RH, Brightling CE, Bradding P, Wardlaw AJ,
 459 Pavord ID. Pathological features and inhaled corticosteroid response of eosinophilic and
 460 non-eosinophilic asthma. *Thorax* 2007.
- 461 11. McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, Fahy JV. A large
 462 subgroup of mild-to-moderate asthma is persistently noneosinophilic. *Am J Respir Crit Care* 463 *Med* 2012; 185: 612-619.
- 464 12. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Arron JR, Koth LL, Fahy JV. T 465 helper type 2-driven inflammation defines major subphenotypes of asthma. *Am J Respir Crit* 466 *Care Med* 2009; 180: 388-395.
- 467 13. Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, Fedorowicz G, Modrusan Z, Fahy
 468 JV, Woodruff PG, Arron JR. Gene Expression Patterns of Th2 Inflammation and Intercellular
 469 Communication in Asthmatic Airways. *J Immunol* 2010: doi:10.4049/jimmunol.1002568.
- 470 14. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D,
 471 Kay AB. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial
 472 subepithelial basement membrane of mild atopic asthmatics. *J Clin Invest* 2003; 112: 1029473 1036.

perpetuity. It is made available under a CC-BY 4.0 International license .

15. Wallin A, Sandstrom T, Cioppa GD, Holgate S, Wilson S. The effects of regular inhaled formoterol

16. Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, Mandal S, Martin J, Mills J,

and budesonide on preformed Th-2 cytokines in mild asthmatics. Respir Med 2002; 96:

Navani N, Rahman NM, Wrightson JM, Munavvar M. British Thoracic Society guideline for

diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax 2013; 68 Suppl 1: i1-

474

475

476

477

478

479

1021-1025.

480 i44. 17. Foundation TR. The R Project for Statistical Computing. [cited 2023 23/05/2023]. Available from: 481 482 http://www.r-project.org/index.html. 483 18. Reimers M, Carey VJ. Bioconductor: an open source framework for bioinformatics and 484 computational biology. Methods Enzymol 2006; 411: 119-134. 485 19. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, 486 Dao-Pick TP, Pantoja C, Erle DJ, Yamamoto KR, Fahy JV. Genome-wide profiling identifies 487 epithelial cell genes associated with asthma and with treatment response to corticosteroids. 488 Proc Natl Acad Sci U S A 2007; 104: 15858-15863. 489 20. Singhania A, Wallington JC, Smith CG, Horowitz D, Staples KJ, Howarth PH, Gadola SD, Djukanovic 490 R, Woelk CH, Hinks TSC. Multitissue Transcriptomics Delineates the Diversity of Airway T Cell 491 Functions in Asthma. Am J Respir Cell Mol Biol 2018; 58: 261-270. 492 21. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy 2008; 38: 872-897. 493 22. Brightling CE, Ammit AJ, Kaur D, Black JL, Wardlaw AJ, Hughes JM, Bradding P. The 494 CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth 495 muscle. Am J Respir Crit Care Med 2005; 171: 1103-1108. 496 23. Khalfaoui L, Symon FA, Couillard S, Hargadon B, Chaudhuri R, Bicknell S, Mansur AH, Shrimanker 497 R, Hinks TSC, Pavord ID, Fowler SJ, Brown V, McGarvey LP, Heaney LG, Austin CD, Howarth 498 PH, Arron JR, Choy DF, Bradding P. Airway remodelling rather than cellular infiltration 499 characterizes both type2 cytokine biomarker-high and -low severe asthma. Allergy 2022. 500 24. Wilson SJ, Ward JA, Sousa AR, Corfield J, Bansal AT, De Meulder B, Lefaudeux D, Auffray C, Loza MJ, Baribaud F, Fitch N, Sterk PJ, Chung KF, Gibeon D, Sun K, Guo YK, Adcock I, Djukanovic R, 501 502 Dahlen B, Chanez P, Shaw D, Krug N, Hohlfeld J, Sandstrom T, Howarth PH, Group UBS. 503 Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED 504 study. Eur Respir J 2016; 48: 1307-1319. 505 25. Hinks TS, Zhou X, Staples KJ, Dimitrov BD, Manta A, Petrossian T, Lum PY, Smith CG, Ward JA, 506 Howarth PH, Walls AF, Gadola SD, Djukanovic R. Innate and adaptive T cells in asthmatic 507 patients: Relationship to severity and disease mechanisms. J Allergy Clin Immunol 2015; 136: 508 323-333. 509 26. Hung LY, Tanaka Y, Herbine K, Pastore C, Singh B, Ferguson A, Vora N, Douglas B, Zullo K, Behrens 510 EM, Li Hui Tan T, Kohanski MA, Bryce P, Lin C, Kambayashi T, Reed DR, Brown BL, Cohen NA, 511 Herbert DR. Cellular context of IL-33 expression dictates impact on anti-helminth immunity. 512 Sci Immunol 2020; 5. 513 27. Staples KJ, Hinks TS, Ward JA, Gunn V, Smith C, Djukanovic R. Phenotypic characterization of lung 514 macrophages in asthmatic patients: overexpression of CCL17. J Allergy Clin Immunol 2012; 515 130: 1404-1412 e1407. 516 28. Pietruszewska W, Fendler W, Podwysocka M, Bialas AJ, Kuna P, Kuprys-Lipinska I, Borowiec M. 517 Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic 518 Rhinosinusitis with Nasal Polyps. Diagnostics (Basel) 2021; 11. 519 29. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, Shikotra A, Carter R, Audusseau S, 520 Hamid Q, Bradding P, Fahy JV, Woodruff PG, Harris JM, Arron JR. Periostin is a systemic 521 biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 522 2012; 130: 647-654. 523 30. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, Heusser CH, Howarth 524 PH, Holgate ST. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and

525	asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J
526	Respir Cell Mol Biol 1994; 10: 471-480.
527	31. Tunon-De-Lara JM, Redington AE, Bradding P, Church MK, Hartley JA, Semper AE, Holgate ST.
528	Dendritic cells in normal and asthmatic airways: expression of the alpha subunit of the high
529	affinity immunoglobulin E receptor (Fc epsilon RI -alpha). Clin Exp Allergy 1996; 26: 648-655.
530	32. Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E,
531	Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas
532	AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P.
533	TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med
534	2015; 7: 301ra129.
535	33. Gieseck RL, 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. <i>Nat Rev</i>
536	Immunol 2018; 18: 62-76.
537	34. Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated
538	macrophages: roles in homeostasis and disease. Annu Rev Immunol 2013; 31: 317-343.
539	35. Goh YP. Henderson NC. Heredia JE. Red Eagle A. Odegaard JI. Lehwald N. Nguyen KD. Sheppard
540	D. Mukundan L. Lockslev RM. Chawla A. Eosinophils secrete IL-4 to facilitate liver
541	regeneration. Proc Natl Acad Sci U S A 2013: 110: 9914-9919.
542	36. Mesnil C. Raulier S. Paulissen G. Xiao X. Birrell MA. Pirottin D. Janss T. Starkl P. Ramery F. Henket
543	M Schleich EN Radermecker M Thielemans K Gillet L Thirv M Belvisi MG Louis R Desmet
544	C Marichal T Bureau E Lung-resident eosinophils represent a distinct regulatory eosinophil
545	subset 1 Clin Invest 2016: 126: 3279-3295
546	37 Monticelli I A Sonnenberg GE Abt MC Alenghat T Ziegler CG Doering TA Angelosanto IM
540	Laidlaw BL Vang CV Sathaliyawala T. Kubota M. Turner D. Diamond IM. Goldrath AW. Earber
5/8	DL Collman RG. Wherry EL Artis D. Innate lymphoid cells promote lung-tissue homeostasis
540	after infection with influenza virus. Nat Immunol 2011: 12: 1045-1054
549	28 Daghar P. Cononbayor AM. Pospard V. Porlin A. Hamidi F. Marot M. Wang I. Ou V. Shrotha V.
	So. Dagner K, Copennaver Aw, Besharu V, Bernin A, Hannur F, Maret W, Wang J, Qu X, Shrestna F,
221	Wu J, Gduller G, Raja R, Aubler W, Kolbeck R, Humbles AA, Pretoidin W. IL-33-512 axis
552	regulates inveloid cell differentiation and activation enabling effective club cell
555	regeneration. Nature communications 2020; 11: 4780.
554	39. MicDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brighting CE,
555	Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Astrima
556	Stratification P. The inflammatory profile of exacerbations in patients with severe refractory
557	eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational
558	study. Lancet Respir Med 2021; 9: 11/4-1184.
559	40. Diver S, Haldar K, McDowell PJ, Busby J, Mistry V, Micieli C, Brown V, Cox C, Yang F, Borg C,
560	Shrimanker R, Ramsheh MY, Hardman T, Arron J, Bradding P, Cowan D, Mansur AH, Fowler
561	SJ, Lordan J, Menzies-Gow A, Robinson D, Matthews J, Pavord ID, Chaudhuri R, Heaney LG,
562	Barer MR, Brightling C, Medical Research Council: Refractory Asthma Stratification P.
563	Relationship between inflammatory status and microbial composition in severe asthma and
564	during exacerbation. Allergy 2022; 77: 3362-3376.
565	41. Agbetile J, Fairs A, Desai D, Hargadon B, Bourne M, Mutalithas K, Edwards R, Morley JP, Monteiro
566	WR, Kulkarni NS, Green RH, Pavord ID, Bradding P, Brightling CE, Wardlaw AJ, Pashley CH.
567	Isolation of filamentous fungi from sputum in asthma is associated with reduced post-
568	bronchodilator FEV1. Clin Exp Allergy 2012; 42: 782-791.
569	42. Ginebaugh SP, Hagner M, Ray A, Erzurum SC, Comhair SAA, Denlinger LC, Jarjour NN, Castro M,
570	Woodruff PG, Christenson SA, Bleecker ER, Meyers DA, Hastie AT, Moore WC, Mauger DT,
571	Israel E, Levy BD, Wenzel SE, Camiolo MJ. Bronchial epithelial cell transcriptional responses
572	to inhaled corticosteroids dictate severe asthmatic outcomes. J Allergy Clin Immunol 2023.
573	43. Leigh R, Mostafa MM, King EM, Rider CF, Shah S, Dumonceaux C, Traves SL, McWhae A, Kolisnik
574	T, Kooi C, Slater DM, Kelly MM, Bieda M, Miller-Larsson A, Newton R. An inhaled dose of
575	budesonide induces genes involved in transcription and signaling in the human airways:

- enhancement of anti- and proinflammatory effector genes. *Pharmacol Res Perspect* 2016; 4: 576 577 e00243.
- 44. Shikotra A, Choy DF, Siddiqui S, Arthur G, Nagarkar DR, Jia G, Wright AK, Ohri CM, Doran E, Butler 578 CA, Hargadon B, Abbas AR, Jackman J, Wu LC, Heaney LG, Arron JR, Bradding P. A CEACAM6-579 580 High Airway Neutrophil Phenotype and CEACAM6-High Epithelial Cells Are Features of
- Severe Asthma. J Immunol 2017; 198: 3307-3317. 581
- 45. Mumby S, Kermani NZ, Garnett JP, Pavlidis S, Wilson SJ, Howarth PJ, Thomas MJ, Adcock IM, 582
- 583 Lopez-Garcia C. CEACAM5 is an IL-13-regulated epithelial gene that mediates transcription in type-2 (T2) high severe asthma. Allergy 2022; 77: 3463-3466. 584

585

TABLES 587

Table 1 – Demographics of the study participants 588

	Healthy – ICS	Healthy – observation	
			p value†
	(n=20)	(n=10)	
Age - years	38 (22-52)	24 (22-33)	0.2
Sex - M/F	8/12	7/3	0.2
BMI (kg/m ²)	24.7 ± 3.7	24.4 ± 2.7	0.8
Ethnicity Caucasian			
(%)	80	70	0.7
Atopic (%)	25	50	0.2
Ex smoker (%)	20	10	0.6
Smoking (pack			
years)	0.0 (0.0-0.0)	0.0 (0.0-0.0)	0.4
FEV ₁ Pre BD (L)	3.32 ± 0.79	4.0 ± 0.93	0.047
FEV ₁ Pre BD (%			
predicted)	103 ± 11	100 ± 8	0.5
FEV1/FVC (%)	82.1 ± 4.6	82.4 ± 3.3	0.9
FeNO (ppb)	16 (11-25)	18 (15-29)	0.4

Blood eosinophils at

screening (x10 ⁹ /L)	0.11 (0.06-0.15)	0.11 (0.08-0.15)	0.8
---------------------------------	------------------	------------------	-----

- 590 Continuous variables are presented as mean \pm SD or median (interquartile range). BD,
- 591 bronchodilator; BMI, body mass index; FVC, forced vital capacity; FeNO, fractional exhaled
- 592 nitric oxide; FEV₁, forced expiratory volume in 1 second; ICS, inhaled corticosteroids.
- ⁵⁹³ †All tests for continuous variables are t-test or Mann Whitney U. For categorical variables, a
- 594 Fischer's exact test was used.
- 595 *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Table 2 – Top upregulated differentially expressed genes

	Bronchial	brushes		Bronchial	biopsies				
Gene	Baseline read count	Log2 fold change	FDR P value	Baseline read count	Log2 fold change	FDR <i>P</i> value	Mean of FDR P values	t Comments and aliases	Functional role
PHACTR3	497	3.59	1.43E-41	325	3.28	4.29E-38	2.14E-38	Phosphatase And Actin Regulator 3; associated with the nuclear scaffold in proliferating cells.	Cytoskeletal changes
HSD11B2	468	1.89	3.22E-41	392	1.81	9.88E-37	4.94E-37	Hydroxysteroid 11-β Dehydrogenase 2: converts cortisol to cortisone, prevents mineralocorticoid receptor activation	on Steroid metabolism
FKBP5	3336	1.88	2.17E-27	5029	1.67	3.14E-20	1.57E-20	Regulates corticosteroid sensitivity; asthma susceptibilty gene.	Steroid metabolism
FAM107A	3486	1.45	6.14E-22	3657	1.60	4.02E-17	2.01E-17	Family With Sequence Similarity 107 Member A; role in actin and microtubule organisation.	Cytoskeletal changes
HIF3A	584	3.18	4.42E-17	990	2.67	5.35E-21	2.21E-17	Hypoxia Inducible Factor 3 Subunit α ; canonical sensor of hypoxia.	Hypoxic sensing
MYLK3	476	1.10	1.19E-40	490	1.47	6.54E-17	3.27E-17	Myosin Light Chain Kinase 3; Immune response to CCR3 signaling in eosinophils, regulates smooth muscle contra	cti Smooth muscle/immune
GP2	341	2.48	1.26E-15	286	3.12	9.81E-28	6.29E-16	Glycoprotein 2; binds pathogens such as enterobacteria.	Innate immune
SULT2B1	1706	1.38	3.05E-17	1199	1.44	2.01E-15	1.02E-15	Hydroxysteroid Sulfotransferase 2; catalyses the sulfate conjugation hormones.	Steroid metabolism
GRAMD2A	2452	1.15	5.37E-24	2309	1.38	2.69E-15	1.35E-15	GRAM Domain Containing 2A; organization of endoplasmic reticulum-plasma membrane contact sites.	Cellular metabolism
SYT8	503	1.12	2.93E-15	470	1.13	2.37E-22	1.46E-15	Synaptotagmin 8; regulate exocytosis of hormones and in intracellular organelles.	Steroid metabolism
SLCO1B3	124	1.94	1.69E-17	111	2.27	5.11E-14	2.55E-14	Solute Carrier Organic Anion Transporter 1B3; transports conjugated steroids, leukotrienes, prostaglandins.	Steroid metabolism
HCAR2	4673	1.10	9.06E-20	3361	1.22	1.15E-13	5.73E-14	Niacin Receptor 1; receptor for niacin and mediates neutrophil apoptosis and anti-inflammatory effect of butyra	ate Anti-inflammatory
PSCA	23905	1.21	9.32E-14	13008	1.87	3.83E-14	6.58E-14	Prostate stem cell antigen; may regulate cell proliferation.	Celll proliferation
TFCP2L1	3228	1.38	2.76E-13	4849	1.40	1.64E-16	1.38E-13	Transcription corepressor activity, and probably Wnt/ β -catenin signaling.	Celll proliferation
PRODH	5268	1.20	5.53E-14	4754	1.10	8.22E-13	4.39E-13	Proline Dehydrogenase 1; catalyses proline catabolism.	Cellular metabolism
TSC22D3	7099	1.12	1.19E-17	8967	1.14	1.55E-12	7.73E-13	Glucocorticoid-Induced Leucine Zipper; mediates anti-inflammatory effects of glucocorticoids in macrophages.	Anti-inflammatory
IFITM10	1872	1.55	4.46E-22	1816	1.23	3.71E-11	1.86E-11	IFITM family functions include controlling cell proliferation, and promoting homotypic cell adhesion.	Celll proliferation
ANPEP	2159	1.16	4.30E-14	1707	1.02	6.28E-11	3.14E-11	Aminopeptidase M, CD13; broad specificity aminopeptidase, promotes angiogenesis, and cell growth.	Celll proliferation
KCNB1	602	1.03	1.83E-15	662	1.28	6.63E-10	3.31E-10	Potassium Voltage-Gated Channel Subfamily B Member 1; neurotransmission and regulation of exocytosis.	Cell signalling
GNMT	704	1.28	2.24099E-12	548	1.10	1.97E-07	9.84E-08	Glycine N-Methyltransferase; regulation of methyl group metabolism.	Cellular metabolism

Top 20 upregulated genes common to both epithelial brushes and bronchial biopsies occurring in the top 24 differentially upregulated genes

599 when ranked by FDR p value. Table ranks genes by arithmetic mean of FDR p values across both tissues.

30

600 Table 3 – Top downregulated differentially expressed genes

601

	Bronchial	brushes		Bronchial	biopsies				
Gene	Baseline	Log2 fold	FDR P	Baseline	Log2 fold	FDR P	Mean of FDF	R Comments and aliases	Functional role
	read count	change	value	read count	change	value	P values		
FCER1A	144	-2.78	2.15E-24	228	-2.25	6.93E-29	1.08E-24	High affinity IgE receptor; expressed on airway mast cells and dendritic cells.	Type 2 immunity
ZNF683	136	-3.33	2.31E-23	131	-3.06	1.32E-20	6.62E-21	Hobit; transcription factor promoting tissue residency in innate and adaptive lymphocytes.	Adaptive immunity
CD207	169	-3.78	3.05E-23	144	-2.90	4.24E-18	2.12E-18	Langerin; C-type lectin with mannose binding specificity, inolved in nonclassical antigen-processing.	Antigen presentation
CCL5	1133	-2.39	1.21E-15	1233	-2.15	2.67E-16	7.37E-16	RANTES; chemoattractant for monocytes, memory T helper cells and eosinophils.	Adaptive immunity
IL33	3885	-1.20	2.18E-22	6985	-1.24	3.70E-15	1.85E-15	Interleukin 33; airway epithelial cell alarmin which acts via ST2 to promote type-2 responses.	Alarmin
CD96	253	-1.62	1.31E-12	399	-1.64	3.49E-14	6.71E-13	TACTILE (T cell activation, increased late expression); involved in adhesion of T and NK cells to target cells.	Cell mediated immunity
TARP	100	-2.50	7.30E-15	112	-1.90	3.18E-10	1.59E-10	TCR Gamma Alternate Reading Frame Protein.	T cell adaptive immunity
TRBC1	353	-2.33	3.39E-10	540	-2.07	3.65E-13	1.70E-10	T cell receptor Beta constant chain 1.	T cell adaptive immunity
TRBC2	463	-2.41	7.16E-10	741	-2.07	2.98E-13	3.58E-10	T cell receptor Beta constant chain 2.	T cell adaptive immunity
PTPN22	165	-1.26	1.43E-09	243	-1.52	5.76E-11	7.42E-10	Protein Tyrosine Phosphatase Non-Receptor Type 22. Regulates Treg frequency and T cell motility.	T cell adaptive immunity
TRAC	539	-1.92	3.37E-09	764	-1.84	4.48E-13	1.68E-09	T cell receptor Alpha constant chain.	T cell adaptive immunity
CPA3	228	-2.26	7.00E-09	913	-1.98	1.51E-09	4.26E-09	Carboxypeptidase A3: mast cell-specific pepridase located in secretory granules.	Type 2 immunity
CD2	566	-1.87	1.23E-08	732	-1.87	9.60E-14	6.14E-09	Lymphocyte-Function Antigen-2; T and NK cell marker and co-stimulatory molecule.	T cell adaptive immunity
CLEC10A	135	-1.71	1.82E-08	199	-2.20	4.39E-14	9.11E-09	C-Type Lectin Domain Containing 10A; CD301: marker for alternatively activated macrophages.	Type 2 immunity
SERPINB10	287	-1.18	1.82E-08	350	-1.42	1.25E-12	9.12E-09	Serpin Family B Member 10; inhibits Th2 cell apoptosis, highly upregulated on airway epithelium by IL-13.	Type 2 immunity
CD8A	516	-1.55	6.40E-07	611	-1.52	5.11E-14	3.20E-07	T cell co-receptor for MHCI restriction.	T cell adaptive immunity
GFI1	133	-1.06	1.73E-06	177	-1.23	2.46E-10	8.64E-07	Growth Factor Independent 1 Transcriptional Repressor; involved in haematopoiesis, especially of neutrophils.	Innate immunity
HLA-DQB2	798	-1.01	9.52E-06	640	-1.51	4.63E-18	4.76E-06	Major histocompatibility complex, class II, DQ beta 2	T cell adaptive immunity
CCR5	295	-1.42	9.97E-05	426	-1.91	1.11E-12	4.99E-05	Ligands include CCL5 (RANTES), MCP-2, MIP-1a, MIP-1b. Chemotactic for T2-induced eosinophils.	Type 2 immunity
PTPN7	248	-1.32	0.00033	312	-1.64	2.36E-10	1.67E-04	Protein Tyrosine Phosphatase Non-Receptor 7; regulation of TCR signaling, early response gene in lymphokine stimulat	ted T cell adaptive immunity

Top 20 downregulated genes common to both epithelial brushes and bronchial biopsies occurring in the top 41 biopsy differentially

603 downregulated genes when ranked by FDR p value. Table ranks genes by arithmetic mean of FDR p values across both tissues.

31

604 FIGURE LEGENDS

605 Figure 1

606	Immunohistochemical analysis of the lamina propria biopsies showing cell counts and
607	remodelling features on participants with available paired data, before and after 4 weeks
608	treatment with inhaled fluticasone or without treatment. The change in numbers of A)
609	eosinophils, with atopic participants shown in red, B) tryptase-positive mast cells, C) chymase-
610	positive mast cells, or D) neutrophils, expressed in absolute counts/mm ² . Changes in area of
611	E) epithelium or F) airway smooth muscle (ASM), expressed as a percentage of biopsy area or
612	of G) reticular basement membrane (RBM) thickness. Horizontal bars represent mean
613	(SD)(mast cells, neutrophils, ASM, epithelium, RBM) or median (IQR) (eosinophils), analysed
614	by unpaired t test or Mann Whitney U respectively.

615

616 Figure 2

617 Changes in gene expression measured by RNAseq in response to 4 weeks treatment with618 inhaled fluticasone. A) Bronchial brush volcano plot. B) Bronchial biopsy volcano plot.



Figure 1

Figure 2

